Literature DB >> 19650861

Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells.

Noritaka Ohga1, Kyoko Hida, Yasuhiro Hida, Chikara Muraki, Kunihiko Tsuchiya, Kohei Matsuda, Yoichi Ohiro, Yasunori Totsuka, Masanobu Shindoh.   

Abstract

The polyphenol epigallocatechin-3 gallate (EGCG) in green tea suppresses tumor growth by direct action on tumor cells and by inhibition of angiogenesis, but it is not known whether it specifically inhibits tumor angiogenesis. We examined the anti-angiogenic effect of EGCG on tumor-associated endothelial cells (TEC), endothelial progenitor cells (EPC), and normal endothelial cells (NEC). EGCG suppressed the migration of TEC and EPC but not NEC. EGCG also inhibited the phosphorylation of Akt in TEC but not in NEC. Furthermore, vascular endothelial growth factor-induced mobilization of EPC into circulation was inhibited by EGCG. MMP-9 in the bone marrow plasma plays key roles in EPC mobilization into circulation. We observed that expression of MMP-9 mRNA was downregulated by EGCG in mouse bone marrow stromal cells. In an in vivo model, EGCG suppressed growth of melanoma and reduced microvessel density. Our study showed that EGCG has selective anti-angiogenic effects on TEC and EPC. It is suggested that EGCG could be a promising angiogenesis inhibitor for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650861     DOI: 10.1111/j.1349-7006.2009.01255.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  29 in total

Review 1.  Bioavailability challenges associated with development of anti-cancer phenolics.

Authors:  Song Gao; Ming Hu
Journal:  Mini Rev Med Chem       Date:  2010-06       Impact factor: 3.862

Review 2.  Emerging role of antioxidants in the protection of uveitis complications.

Authors:  U C S Yadav; N M Kalariya; K V Ramana
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner.

Authors:  Takahiro Osawa; Noritaka Ohga; Yasuhiro Hida; Kazuko Kitayama; Kosuke Akiyama; Yuichiro Onodera; Manabu Fujie; Nobuo Shinohara; Masanobu Shindoh; Katsuya Nonomura; Kyoko Hida
Journal:  Cancer Sci       Date:  2012-04-17       Impact factor: 6.716

4.  Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells.

Authors:  Abigail Peairs; Rujuan Dai; Lu Gan; Samuel Shimp; M Nichole Rylander; Liwu Li; Christopher M Reilly
Journal:  Cell Mol Immunol       Date:  2010-02-08       Impact factor: 11.530

Review 5.  EPCs and pathological angiogenesis: when good cells go bad.

Authors:  Sergio Li Calzi; Matthew B Neu; Lynn C Shaw; Jennifer L Kielczewski; Nicanor I Moldovan; Maria B Grant
Journal:  Microvasc Res       Date:  2010-02-25       Impact factor: 3.514

Review 6.  Botanicals for the prevention and treatment of cutaneous melanoma.

Authors:  Deeba N Syed; Hasan Mukhtar
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-12       Impact factor: 4.693

Review 7.  Emerging phytochemicals for prevention of melanoma invasion.

Authors:  Virginia Jones; Santosh K Katiyar
Journal:  Cancer Lett       Date:  2013-03-06       Impact factor: 8.679

Review 8.  Heterogeneity of tumor endothelial cells.

Authors:  Kyoko Hida; Noritaka Ohga; Kosuke Akiyama; Nako Maishi; Yasuhiro Hida
Journal:  Cancer Sci       Date:  2013-09-12       Impact factor: 6.716

9.  Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.

Authors:  Li Cong; Nako Maishi; Dorcas A Annan; Marian F Young; Hirofumi Morimoto; Masahiro Morimoto; Jin-Min Nam; Yasuhiro Hida; Kyoko Hida
Journal:  Breast Cancer Res       Date:  2021-05-10       Impact factor: 6.466

10.  Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis.

Authors:  T Osawa; N Ohga; K Akiyama; Y Hida; K Kitayama; T Kawamoto; K Yamamoto; N Maishi; M Kondoh; Y Onodera; M Fujie; N Shinohara; K Nonomura; M Shindoh; K Hida
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.